3 results match your criteria: "St. John of Brother of God Hospital[Affiliation]"
A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI.
Int J Cardiol
January 2022
Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, National Institute for Health (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust and University of Oxford, John Radcliffe Hospital, Oxford, UK. Electronic address:
Background: Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfusion injury, which is caused by multiple pathways activated by rapid tissue reoxygenation and the generation of reactive oxygen species (ROS). FDY-5301 contains sodium iodide, a ubiquitous inorganic halide and elemental reducing agent that can act as a catalytic anti-peroxidant.
View Article and Find Full Text PDFWide QRS alternans caused by propafenone toxicity.
Acta Cardiol
February 2019
a Cardiology Department , St. John of Brother of God Hospital, Budapest , Hungary.
Ventricular Tachycardia Caused by Ibrutinib.
J Emerg Med
August 2017
Department of Cardiology, St. John of Brother of God Hospital, Budapest, Hungary.